Phaseline

Targets › CCDC6

CCDC6 (Coiled-coil domain-containing protein 6): drug programs, companies and trials

4 programs from 3 companies in 14 trials: 7 Phase 2, 3 Phase 3, 2 Phase 4, 2 Phase 1; Oncology; next expected readout Nov 2026.

Acts as a structural scaffold that organizes free PP2Ac into a configuration that FBXO42 can recognize and ubiquitinate, leading to its proteasomal degradation. Also interacts independently with PPP4C through a mechanism distinct from FBXO42-mediated ubiquitination. (UniProt, Q16204)

Open in Phaseline: the race on CCDC6, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Rigel PharmaceuticalsPralsetinib
Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor
RET, CCDC6, KIF5BPhase 4NSCLC (Non-small Cell Lung Cancer)Jul 2027
Eli LillySelpercatinib
Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
RET, KIF5B, CCDC6Phase 3Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Solid Tumor; Medullary Thyroid Cancer …Feb 2027
Eli LillySelpercatinib (LY3527723)
Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor
RET, KIF5B, CCDC6Phase 3Medullary Thyroid CancerNov 2027
RochePralsetinib
Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor
RET, CCDC6, KIF5BPhase 2Non-small Cell Lung Cancer; Advanced Thyroid Cancer Patients Who Received Target Therapy; Lung Cancer Stage IIINov 2026

Conditions

Non-Small Cell Lung Cancer (2) Medullary Thyroid Cancer (2) Non-small Cell Lung Cancer (1) Advanced Thyroid Cancer Patients Who Received Target Therapy (1) Lung Cancer Stage III (1) Carcinoma, Non-Small-Cell Lung (1) Solid Tumor (1) Recurrent Lung Non-Small Cell Carcinoma (1) Hematopoietic and Lymphatic System Neoplasm (1) Malignant Thyroid Gland Neoplasm (1) Differentiated Thyroid Cancer (1) NSCLC (Non-small Cell Lung Cancer) (1)

Modalities

small molecule (3), mixed (1)

Companies

Eli Lilly (2) Roche (1) Rigel Pharmaceuticals (1)

Related targets

RET (4) KIF5B (4)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.